Royleanone Derivatives From Plectranthus spp. as a Novel Class of P-Glycoprotein Inhibitors
Cancer is among the leading causes of death worldwide. One of the most challenging obstacles in cancer treatment is multidrug resistance (MDR). Overexpression of P-glycoprotein (P-gp) is associated with MDR. The growing incidence of cancer and the development of MDR drive the search for novel and mo...
Main Authors: | Catarina Garcia, Vera M. S. Isca, Filipe Pereira, Carlos M. Monteiro, Epole Ntungwe, Francisco Sousa, Jelena Dinic, Suvi Holmstedt, Amílcar Roberto, Ana Díaz-Lanza, Catarina P. Reis, Milica Pesic, Nuno R. Candeias, Ricardo J. Ferreira, Noélia Duarte, Carlos A. M. Afonso, Patrícia Rijo |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-11-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2020.557789/full |
Similar Items
-
Activity to Breast Cancer Cell Lines of Different Malignancy and Predicted Interaction with Protein Kinase C Isoforms of Royleanones
by: Vera M. S. Isca, et al.
Published: (2020-05-01) -
Biological activity screening of seven Plectranthus species
by: Epole Ntungwe N, et al.
Published: (2017-07-01) -
Preliminary Biological Activity Screening of <i>Plectranthus</i> spp. Extracts for the Search of Anticancer Lead Molecules
by: Epole Ntungwe, et al.
Published: (2021-04-01) -
Synthesis and Cytotoxicities of Royleanone Derivatives
by: Cheng-Ji Li, et al.
Published: (2018-06-01) -
Parvifloron D from <i>Plectranthus</i> <i>strigosus</i>: Cytotoxicity Screening of <i>Plectranthus</i> spp. Extracts
by: Catarina Garcia, et al.
Published: (2019-10-01)